title: Effect of anticancer drugs on patients with and without initially reduced saliva flow.
abstract: We reported earlier that despite the well-known cytolytic effect of anticancer drugs, mean stimulated salivary flow rates were not significantly affected during a 12-month follow-up of patients undergoing treatment for lymphomas (Laine et al. Oral Oncol, Eur J Cancer 1992, 28B, 125-128). Therefore, we set out to investigate in more detail the flow rates and composition of salivas in these patients, but now grouped according to their initial flow rate values, which had been assessed before the start of treatment. 49 patients of the original material (30 men and 19 women, mean age 49.9 years) were divided into hyposalivation and normal flow rate groups, according to their baseline values. Stimulated saliva flow > or = 0.8 ml/min was regarded as the limit for a normal flow rate. 11 patients were found to have reduced flow at baseline (hyposalivation group), while 38 patients had normal flow rate. Analysis of repeated saliva samples taken during the 12-month follow-up showed that flow rates remained significantly lower in the hyposalivation group compared with those of the other group (P < 0.001). Further, the concentrations of total protein, albumin, lysozyme, amylase, IgG, IgA and IgM were, and remained, all significantly higher in patients of the hyposalivation group. Counts for salivary mutans streptococci and yeasts were higher and remained significantly so among patients with hyposalivation than among those with normal flow rate while lactobacilli counts were higher in patients with normal initial flow rate.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Faculty of Dentistry, University of Kuopio, Finland.
authors.forename: J H
authors.initials: JH
authors.lastname: Meurman
authors.forename: P
authors.initials: P
authors.lastname: Laine
authors.forename: C
authors.initials: C
authors.lastname: Lindqvist
authors.forename: S
authors.initials: S
authors.lastname: Pyrhonen
authors.forename: L
authors.initials: L
authors.lastname: Teerenhovi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D012463:Saliva / Q000737:chemistry / Q000187:drug effects* / Q000382:microbiology; D012472:Salivation / Q000187:drug effects*; D014987:Xerostomia / Q000382:microbiology / Q000503:physiopathology*